Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

NCT05967351

Enrolling By InvitationPhase 3

Sponsor: Sarepta Therapeutics, Inc.

Conditions: Duchenne Muscular Dystrophy

Interventions: delandistrogene moxeparvovec

Countries: United States, Belgium, Germany, Hong Kong, Italy, Japan, Spain, Taiwan

The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.

Eligibility overview

Sex: MALE

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Received delandistrogene moxeparvovec for Duchenne muscular dystrophy in a previous clinical study.
* Has (a) parent(s) or legal caregiver(s) or is ≥18 years of age and able to understand and comply with the study visit schedule and all other protocol requirements.

Exclusion Criteria:

* Not applicable
Locations (38)
  • Little Rock, Arkansas, United States
  • Los Angeles, California, United States
  • Palo Alto, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Gainesville, Florida, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • St Louis, Missouri, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Durham, North Carolina, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Dallas, Texas, United States
  • Salt Lake City, Utah, United States
  • Norfolk, Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Ghent, East Flanders, Belgium
  • Essen, North Rhine-Westphalia, Germany
  • Hong Kong, Hong Kong
  • Genova, Italy
  • Milan, Italy
  • Roma, Italy
  • Kobe, Hyōgo, Japan
  • Kodaira, Tokyo, Japan
  • + 8 more on CT.gov